In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Steven D ForsytheNeuroendocrine Cancer Therapy Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-4099-6642 Srujana V YellapragadaNeuroendocrine Cancer Therapy Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0009-0009-3512-8796 Tracey PuSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-7880-2183 Darryl NousomeCCR Collaborative Bioinformatics Resource, Office of Science and Technology Resources, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-5259-8599 Samarth MathurCCR Collaborative Bioinformatics Resource, Office of Science and Technology Resources, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-6446-5718 Dilara AkbulutLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-2288-9667 Stephen G AndrewsNeuroendocrine Cancer Therapy Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Kamala A KennyNeuroendocrine Cancer Therapy Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Martha QuezadoLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0009-0004-0941-8662 Margaret C CamCCR Collaborative Bioinformatics Resource, Office of Science and Technology Resources, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-8190-9766 Jaydira Del RiveroDevelopmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-9710-4030 Serguei KozlovCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0001-5253-2867 Jonathan M HernandezSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-7529-0557 Naris NilubolSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-7348-7804 James P MadiganNeuroendocrine Cancer Therapy Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-0503-3704 Samira M SadowskiNeuroendocrine Cancer Therapy Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-7538-9431 Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · 2019 to 2025
$3932.6MTargeted Therapy in Neuroendocrine CancerZIABC011899 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SADOWSKI, SAMIRA · 2019 to 2025
$10.0MIntramural NIH HHS ZIA BC011899NIH HHS 75N91019D00024
6 · The paper itselfAbstract
Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are a rare subset of cancers with increasing incidence. Due to their slow growth and lack of targetable mutations, the identification of effective treatments remains limited. One reason behind this stagnation is the lack of applicable, accurate study models. One solution is patient tumor organoids (PTOs) that maintain tumor characteristics and can scale for high throughput assays. In this study, PTOs were generated from 35 tumors of pancreatic, small intestinal, and gastric origin, obtained from 17 patients. Important subtypes including hormone functional and
Indexed as
Neuroendocrine TumorsOrganoidsPancreatic NeoplasmsPrecision MedicineAnimalsFemaleHumansMaleMiceXenograft Model Antitumor Assays
Identifiers
PMID42497252
PMCPMC13398536
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390